Last reviewed · How we verify
Antiandrogen
Antiandrogen is a Small molecule drug developed by Göteborg University. It is currently in Phase 3 development. Also known as: Eulexin, Casodex.
Antiandrogens are a class of small molecule drugs that act as androgen receptor antagonists, blocking the effects of androgens like testosterone and dihydrotestosterone in the body. They are used to treat conditions such as prostate cancer, breast neoplasms, and prostate cancer with bone metastases, and are often used in conjunction with other treatments like androgen deprivation therapy.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Antiandrogen |
|---|---|
| Also known as | Eulexin, Casodex |
| Sponsor | Göteborg University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment (PHASE3)
- Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer (PHASE2)
- PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer (PHASE2, PHASE3)
- PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer (PHASE2, PHASE3)
- Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study (PHASE3)
- Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer (NA)
- Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (PHASE2)
- Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antiandrogen CI brief — competitive landscape report
- Antiandrogen updates RSS · CI watch RSS
- Göteborg University portfolio CI
Frequently asked questions about Antiandrogen
What is Antiandrogen?
Who makes Antiandrogen?
Is Antiandrogen also known as anything else?
What development phase is Antiandrogen in?
Related
- Manufacturer: Göteborg University — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Eulexin, Casodex